- Home
- TNGX vs AUDC Comparison
TNGX vs AUDC Comparison
Compare TNGX & AUDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNGX
- AUDC
- Stock Information
- Founded
- TNGX 2014
- AUDC 1992
- Country
- TNGX United States
- AUDC Israel
- Employees
- TNGX N/A
- AUDC N/A
- Industry
- TNGX Biotechnology: Pharmaceutical Preparations
- AUDC Telecommunications Equipment
- Sector
- TNGX Health Care
- AUDC Utilities
- Exchange
- TNGX Nasdaq
- AUDC Nasdaq
- Market Cap
- TNGX 317.4M
- AUDC 279.1M
- IPO Year
- TNGX N/A
- AUDC 1999
- Fundamental
- Price
- TNGX $1.14
- AUDC $8.61
- Analyst Decision
- TNGX Strong Buy
- AUDC Buy
- Analyst Count
- TNGX 7
- AUDC 3
- Target Price
- TNGX $12.33
- AUDC $11.67
- AVG Volume (30 Days)
- TNGX 532.3K
- AUDC 107.8K
- Earning Date
- TNGX 05-12-2025
- AUDC 05-06-2025
- Dividend Yield
- TNGX N/A
- AUDC 2.08%
- EPS Growth
- TNGX N/A
- AUDC 57.57
- EPS
- TNGX N/A
- AUDC 0.56
- Revenue
- TNGX $42,069,000.00
- AUDC $242,474,000.00
- Revenue This Year
- TNGX N/A
- AUDC $5.11
- Revenue Next Year
- TNGX N/A
- AUDC $3.81
- P/E Ratio
- TNGX N/A
- AUDC $15.06
- Revenue Growth
- TNGX 15.17
- AUDC N/A
- 52 Week Low
- TNGX $1.11
- AUDC $7.70
- 52 Week High
- TNGX $12.02
- AUDC $12.72
- Technical
- Relative Strength Index (RSI)
- TNGX 36.06
- AUDC 39.54
- Support Level
- TNGX $1.03
- AUDC $8.01
- Resistance Level
- TNGX $1.56
- AUDC $9.84
- Average True Range (ATR)
- TNGX 0.15
- AUDC 0.31
- MACD
- TNGX -0.01
- AUDC -0.06
- Stochastic Oscillator
- TNGX 17.74
- AUDC 32.79
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.
About AUDC AudioCodes Ltd.
AudioCodes Ltd develops and sells onverged voice over IP and data networking solutions, products and applications to service providers and channels, OEMs, network equipment providers and system integrators. Its products include IP phones, session border controllers, voice applications, multi-service business routers, digital and analog media gateways, among others. The company generates revenues from the sale of products through a direct sales force and sales representatives. Its geographic segments are Israel, Americas, Europe, and the Far East. It derives a majority of the revenues from Americas segment.